RxDoctor Payments Data

Jessica Bussey

Family · Coventry Township, OHNPI 1801399415

Payments from drug & device makers

$3,038in general payments, 2019–2025

Across 350 payments — averaging $8.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$1K
  • AbbVie$990
  • Biohaven Pharmaceuticals, Inc.$304
  • Amgen$188
  • Lilly USA, LLC$120
  • AstraZeneca$71
  • plus $338 from 11 others

What the payments were for

  • Food & beverage$2,90396%
  • Education$1354%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,038 in reported general payments places this provider in the 85th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$66,490
Medicare patients
112
Services billed
11,011

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate588$688,257
QuliptaAtogepant313$383,875
BotoxOnabotulinumtoxina214$310,376
Radicava OrsEdaravone20$291,583
Kesimpta PenOfatumumab27$281,788
Emgality PenGalcanezumab-Gnlm257$254,711
Ajovy AutoinjectorFremanezumab-Vfrm229$244,490
UbrelvyUbrogepant205$219,447
Aimovig AutoinjectorErenumab-Aooe189$170,428
IngrezzaValbenazine Tosylate20$148,627
Rebif RebidoseInterferon Beta-1a/Albumin14$148,022
VyeptiEptinezumab-Jjmr18$68,746
XeljanzTofacitinib Citrate11$63,950
NucyntaTapentadol Hcl40$59,296
ReyvowLasmiditan Succinate58$49,588

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Botox, Ubrelvy, Vraylar$990$929,698743 claims
PfizerNurtec Odt, Xeljanz, Zavzpret$63$780,649621 claims
Neurocrine Biosciences, Inc.Ingrezza$16$148,62720 claims
Lilly USA, LLCReyvow$120$49,58858 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,812 family providers in Ohio.

Other family in Coventry Township

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →